Cobalt Therapeutics, LLC offers products that fit seamlessly into current clinical
settings and enhance their therapeutic offerings to patients, decrease costs,
and improve outcomes.
These programs have been evaluated in randomized, controlled trials
and published in leading peer-reviewed journals.
SHADE is a ten week program that has been studied in
randomized, controlled trials and published in the field’s leading journal (Addiction) in 2009.
The program has been demonstrated to significantly reduce substance use, drinking, binge drinking,
hazardous use and depression. SHADE has been implemented at leading centers in the United States
and internationally to enhance outcomes and improve standardization of care.
The SHADE program was developed by Dr. Frances Kay-Lambkin and Prof. Amanda Baker.
“…the the first evidence-based computerised treatment to be developed and tested for treating both
disorders within the one treatment package.”